Chairman of the Executive Committee, CEO, Executive Director
Dr. Roch Doliveux has served as NonExecutive Director of UCB S.A. since April 27, 2017. He served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of the Company between January 1, 2005 and December 31, 2014. He was Deputy Chairman of Executive Committee, Director General of the Pharma Sector of the Company between October 2003 and January 1, 2005. He is Doctor in Veterinarian Medicine from MaisonsAlfort, Mr. Doliveux is also Laureate of the Faculty of Medicine, Creteil, and holds a Masters of Business Administration from INSEAD or Institut Europeen dAdministration des Affaires, France with distinction. He joined the pharmaceutical industry early, first at CibaGeigy in Switzerland, in Peru and in France, and then at ScheringPlough Corporationrationration in various positions, including President of ScheringPlough International. Then, Roch Doliveux joined the Pierre Fabre group a Chief Executive Officer of Pierre Fabre Pharmaceuticals
Age: 60 Chairman Since 2017Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB on January 1, 2005. He is a member of the Board of Directors of UCB, Member of the Board of Stryker Corporationrationrationration in the United States, as well as a member of the Board of the European Federation of Pharmaceutical Association, the Innovative Medicines Initiative which is a publicprivate partnership between the European Union and EFPIA, WELBIO, the INSEAD International Council and Chairman of the Caring Entrepreneurship Fund .
Roch Doliveux Latest Insider Activity
Management EfficiencyThe company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
Entity SummaryUCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.
UCB SA Leadership Team
Stock Performance Indicators
Also Currentnly Active
Purchased over 300 shares of
Purchased over 70 shares of